Workflow
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates
ANGOAngioDynamics(ANGO) ZACKS·2025-01-08 13:45

Company Performance - AngioDynamics reported a quarterly loss of 0.04pershare,betterthantheZacksConsensusEstimateofalossof0.04 per share, better than the Zacks Consensus Estimate of a loss of 0.11, and an improvement from a loss of 0.05pershareayearago,representinganearningssurpriseof63.640.05 per share a year ago, representing an earnings surprise of 63.64% [1] - The company posted revenues of 72.85 million for the quarter ended November 2024, surpassing the Zacks Consensus Estimate by 2.36%, although this is a decline from year-ago revenues of 79.07million[2]−Overthelastfourquarters,AngioDynamicshasexceededconsensusEPSestimatesthreetimesandtoppedconsensusrevenueestimatestwotimes[2]StockOutlook−AngioDynamicsshareshaveincreasedapproximately2.679.07 million [2] - Over the last four quarters, AngioDynamics has exceeded consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Outlook - AngioDynamics shares have increased approximately 2.6% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is -0.11 on revenues of 70.75million,andforthecurrentfiscalyear,itis−70.75 million, and for the current fiscal year, it is -0.41 on revenues of $284.07 million [7] - The estimate revisions trend for AngioDynamics is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which AngioDynamics belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]